Munich Cancer Registry



- ▶ Survival
- ▶ Selection Matrix
- ▶ Homepage
- ▶ Deutsch

ICD-10 C73: Anaplastic thyroid ca.

Incidence and Mortality

Year of diagnosis	1998-2020
Patients	278
Diseases	278
Creation date	12/21/2021
Database export	12/20/2021
Population	4.95 m



Munich Cancer Registry
Cancer Registry Bavaria - Upper Bavaria Regional Center
at Klinikum Grosshadern/IBE
Marchioninistr. 15
Munich, 81377
Germany

https://www.tumorregister-muenchen.de/en

https://www.tumorregister-muenchen.de/en/facts/base/bC73A_E-ICD-10-C73-Anaplastic-thyroid-ca.-incidence-and-mortality.pdf

Index of figures and tables

Fig./Tbl	I.	Page
1	Annual cases, DCO, mult. malignancies, follow-up / yr	4
2	Incidence by year of diagnosis	7
3	Age distribution parameters by year of diagnosis	8
4	Age distribution by 5-year age group and sex	11
5	Age-specific incidence, DCO rate, proportion malignancies	12
6	Age distribution and age-specific incidence (chart)	13
6a	Age-specific incidence internationally (chart)	14
7	Standardized incidence ratio of further malignancies	15
8a	Map of cancer incidence (BRD-S) by county (chart)	17
8b	Standardized incidence ratio (SIR) by county (chart)	18
9a	Pts incident cohorts and mortality / yr	19
9b	Incidence and mortality by year of diagnosis	20
9c	Cancer-related deaths, death certification available / yr	21
10	Medians of age at death / yr	22
11	Mortality by year of death	24
12	Distribution of age at death	26
13	Age-specific mortality	27
14	Further malignancies in deaths	28
15	Age-specific mortality (first primaries)	29
16	Age-specific mortality (single primaries)	30
17	Age distribution and age-specific mortality (chart)	31
18a	Map of cancer mortality (BRD-S) by county (chart)	32
18b	Standardized mortality ratio (SMR) by county (chart)	33

Global Statements about the statistics on the Internet – Baseline Statistics (grey button ——), Survival (red button ——)

In these analyses, the clinics and physicians of Upper Bavaria and the city and county of Landshut[#], with a total of 4.69 million inhabitants, account for the frequency of cancer diseases^{##} and the achieved long term results. Additionally, the long term survival evaluated by the Munich Cancer Registry (MCR) is compared with the results of the population-based registry in the USA (SEER), which is useful for checking the consistency of the data on an international level.

In comparing several tables, inconsistent figures may be detected. This is based on the fact that different patient cohorts are included in the base calculation, for example when proportions of multiple tumors or DCO-cases**** are concerned. In other cases the individual tumor diagnosis is the basis for calculation, for example with incidence.

The foot notes describe the currentness of the data. The baseline statistics and survival data are updated annually. This yearly analysis comprises the Annual Report of the MCR.

Clinics and physicians have access to essentially more detailed data, with which they can check, compare and in the best case optimize their own data and results.

We would be pleased to receive corrections, critique and useful suggestions. Just send an e-mail to tumor@ibe.med.uni-muenchen.de.

Munich Cancer Registry, December 2021

- Base data has been collected since 1998. An increase in new diseases is apparent, which is an effect of two extensions in the MCR catchment area (from a base population of 2.65 million to 4.10 in 2002, and to 4.69 million in 2007).
- Due to the high frequency and good prognosis of non-malignant skin cancer (C44), no systematic ascertainment is performed for this diagnosis. C44 is not designated as a primary, but rather as a secondary tumor.
- ### DCO (death certificate only) identifies a cancer case that first becomes available to the MCR through the death certificate.

ICD-10 codes (ICD-10 2015) used for specifying cancer site

Code	Description
C73	Malignant neoplasm of thyroid gland
in o	case of coexisting one of the following

Morphology codes (ICD-O-3 2013) used for specifying cancer site

Code	Description
8020/3 8021/3	Carcinoma undifferentiated, NOS Anaplastic carcinoma, NOS

INCIDENCE

Table 1

Cases with invasive cancer by year of diagnosis, proportions of DCO, further malignancies, deaths, and active follow-up (ALL PATIENTS) (incl. DCO)

				_			
				Prop. at least	D		
				1 further	Prop. at least		
				malign.	1 further		Prop.
	All	DCO	Prop.	prior +	malign.	Prop.	actively
Year of	cases	cases	DCO	synchron.	after	deaths	followed
diagnosis	n	n	%	%	%	%	%
aragnosis	11	11	O	o	°	o	0
1998	5			20.0	4.0	100.0	100.0
1999	11			12.5	4.1	81.8	100.0
2000	6			27.3	4.3	83.3	100.0
2001	7			24.1	4.0	100.0	100.0
2002	14			16.3	4.1	92.9	100.0 #
2003	11 /			16.7	3.5	90.9	100.0
2004	11			16.9	3.7	100.0	100.0
2005	14			17.7	3.9	92.9	100.0
2006	13			15.2	3.6	92.3	92.3
2007	22			14.0	2.8	86.4	95.5 #
2008	12			15.1	2.5	83.3	100.0
2009	19			15.9	2.7	94.7	100.0
2010	10			17.4	3.1	100.0	100.0
2011	22			19.8	3.4	90.9	100.0
2012	14			20.4	3.1	100.0	100.0
2013	16			20.3	3.6	93.8	100.0
2014	15			19.8	2.9	93.3	93.3
2015	12			20.5	1.9	83.3	100.0
2016	9			20.2	0.0	100.0	100.0
2017	10			20.6	0.0	90.0	90.0
2018	11			20.1	0.0	72.7	100.0
2019	12			20.7	0.0	75.0	100.0
2020	2			20.9	0.0	50.0	100.0 ##
1998-2020	278			20.9	4.0	90.3	98.6

278 cases diagnosed 1998-2020 are related to a total of 278 patients. Currently, in 73 (26.3 %) of these 278 patients more than one malignancy of any cancer type has been registered. Hereby, groups of 63 / 8 / 2 (22.7 % / 2.9 % / 0.7 %) patients exist having 2 / 3 / 4+ malignancies.

- # The increases of incident cases in 2002 and 2007 reflect the expansion to additional registry areas.
- ## Please be aware that data of recent annual patient cohorts may not yet be fully processed. The years under evaluation can be retreived from the respective headings.

How to interpret:

In 2018, a subgroup of 11 cases has been diagnosed, of which 20.1 % previously and/or concurrently (synchronously) had at least one other malignancy of any cancer type. In 0.0 % of cases, at least one new malignancy has occurred during the follow-up period (all numbers refer to the date of the database export, see cover sheet).

Table 1a

Cases with invasive cancer by year of diagnosis, proportions of DCO, further malignancies, deaths, and active follow-up (MALES) (incl. DCO)

					Danon			
					Prop. at least	Dron		
					1 further	Prop. at least		
								D
			DOO	D	malign.	1 further	D	Prop.
V	Males	Malaa	DCO	Prop.	prior +	malign. after	Prop. deaths	actively
Year of		Males	cases	DCO	synchron.	% arcer	%	followed
diagnosis	n	ે	n	6	6	6	6	%
1998	1	20.0			100.0	4.5	100.0	100.0
1999	5	45.5			16.7	4.5	100.0	100.0
2000	3	50.0			33.3	4.8	66.7	100.0
2001	4	57.1			23.1	3.9	100.0	100.0
2002	4	28.6			17.6	4.1	75.0	100.0 #
2003	6	54.5			17.4	3.2	83.3	100.0
2004	5	45.5			17.9	3.4	100.0	100.0
2005	5	35.7			21.2	3.6	100.0	100.0
2006	5	38.5			18.4	2.6	100.0	100.0
2007	7	31.8			15.6	1.4	85.7	100.0 #
2008	4	33.3			16.3	0.0	75.0	100.0
2009	6	31.6			14.5	0.0	83.3	100.0
2010	3	30.0			17.2	0.0	100.0	100.0
2011	8	36.4			21.2	0.0	75.0	100.0
2012	7	50.0			20.5	0.0	100.0	100.0
2013	8	50.0			21.0	0.0	87.5	100.0
2014	7	46.7			21.6	0.0	100.0	100.0
2015	6	50.0			23.4	0.0	83.3	100.0
2016	4	44.4			22.4	0.0	100.0	100.0
2017	6	60.0			23.1	0.0	100.0	100.0
2018	4	36.4			22.2	0.0	100.0	100.0
2019	5	41.7			23.0	0.0	60.0	100.0
2020	1	50.0			23.7	0.0	100.0	100.0 ##
1998-2020	114	41.0			23.7	4.5	89.5	100.0

114 cases diagnosed 1998-2020 are related to a total of 114 patients. Currently, in 34 (29.8 %) of these 114 patients more than one malignancy of any cancer type has been registered. Hereby, groups of 28 / 5 / 1 (24.6 % / 4.4 % / 0.9 %) patients exist having 2 / 3 / 4+ malignancies.

- # The increases of incident cases in 2002 and 2007 reflect the expansion to additional registry areas.
- ## Please be aware that data of recent annual patient cohorts may not yet be fully processed. The years under evaluation can be retreived from the respective headings.

How to interpret:

In 2018, a subgroup of 4 cases has been diagnosed, of which 22.2 % previously and/or concurrently (synchronously) had at least one other malignancy of any cancer type. In 0.0 % of cases, at least one new malignancy has occurred during the follow-up period (all numbers refer to the date of the database export, see cover sheet).

Table 1b

Cases with invasive cancer by year of diagnosis, proportions of DCO, further malignancies, deaths, and active follow-up (FEMALES) (incl. DCO)

					Prop. at least	Prop.		
					1 further	\ _		
					malign.	1 further		Prop.
			DCO	Prop.	prior +	malign.	Prop.	actively
Year of	Females	Females	cases	DCO	synchron.	after	deaths	followed
diagnosis	n	%	n	양	%	90	ଚ	90
1998	4	80.0			0.0	3.7	100.0	100.0
1999	6	54.5			10.0	3.8	66.7	100.0
2000	3	50.0			23.1	4.0	100.0	100.0
2001	3	42.9			25.0	4.1	100.0	100.0
2002	10	71.4			15.4	4.1	100.0	100.0 #
2003	5	45.5			16.1	3.7	100.0	100.0
2004	6	54.5			16.2	3.8	100.0	100.0
2005	9	64.3			15.2	4.0	88.9	100.0
2006	8 /	61.5			13.0	4.3	87.5	87.5
2007	15/	68.2			13.0	3.7	86.7	93.3 #
2008	8	66.7			14.3	4.3	87.5	100.0
2009	13	68.4			16.7	4.8	100.0	100.0
2010	7\	70.0			17.5	5.6	100.0	100.0
2011	14	63.6			18.9	6.3	100.0	100.0
2012	7	50.0			20.3	6.0	100.0	100.0
2013	8	50.0			19.8	6.8	100.0	100.0
2014	8	53.3			18.7	5.6	87.5	87.5
2015	6	50.0			18.6	3.4	83.3	100.0
2016	5	55.6			18.6	0.0	100.0	100.0
2017	4	40.0			18.8	0.0	75.0	75.0
2018	7	63.6			18.6	0.0	57.1	100.0
2019	7	58.3			19.0	0.0	85.7	100.0
2020	1	50.0			18.9	0.0		100.0 ##
1998-2020	164	59.0			18.9	3.7	90.9	97.6

164 cases diagnosed 1998-2020 are related to a total of 164 patients. Currently, in 39 (23.8 %) of these 164 patients more than one malignancy of any cancer type has been registered. Hereby, groups of 35/3/1 (21.3 % / 1.8 % / 0.6 %) patients exist having 2 / 3 / 4+ malignancies.

- # The increases of incident cases in 2002 and 2007 reflect the expansion to additional registry areas.
- ## Please be aware that data of recent annual patient cohorts may not yet be fully processed. The years under evaluation can be retreived from the respective headings.

How to interpret:

In 2018, a subgroup of 7 cases has been diagnosed, of which 18.6 % previously and/or concurrently (synchronously) had at least one other malignancy of any cancer type. In 0.0 % of cases, at least one new malignancy has occurred during the follow-up period (all numbers refer to the date of the database export, see cover sheet).

Table 2

Incidence measures by year of diagnosis including DCO cases (with respect to registry area expansion from 2.65 to 4.10 m as of 2002, and from 4.10 to 4.94 m as of 2007, respectively)

			Males	Fem.	Males	Fem.	Males	Fem.	Males	Fem.
Year of	Males	Females	Inc.	Inc.	Inc.	Inc.	Inc.	Inc.	Inc.	Inc.
diagnosis	n	n	raw	raw	WS	WS	ES	ES	BRD-S	BRD-S
1998	1	4	0.1/	0.3	0.1	0.2	0.1	0.3	0.1	0.3
1999	5	6	0.4	0.5	0.3	0.2	0.4	0.3	0.5	0.4
2000	3	3 /	0.3	0.2	0.1	0.2	0.2	0.2	0.3	0.2
2001	4	3 /	0.3	0.2	0.2	0.1	0.3	0.2	0.3	0.2
2002	4	10	0.2	0.5	0.1	0.2	0.2	0.3	0.2	0.5
2003	6	5	0.3	0.3	0.2	0.1	0.3	0.1	0.4	0.2
2004	5	6	0.3	0.3	0.1	0.1	0.2	0.2	0.3	0.2
2005	5	9	0.3	0.5	0.1	0.2	0.2	0.3	0.4	0.4
2006	5	8	0.3	0.4	0.1	0.2	0.2	0.3	0.3	0.3
2007	7	15	0.3	0.6	0.2	0.3	0.3	0.4	0.4	0.5
2008	4	8	0.2	0.3	0.1	0.1	0.1	0.2	0.2	0.3
2009	6	13	0.3	0.6	0.1	0.2	0.2	0.3	0.3	0.4
2010	3 /	7	0.1	0.3	0.0	0.1	0.1	0.1	0.1	0.2
2011	8	14	0.4	0.6	0.2	0.2	0.3	0.3	0.3	0.5
2012	7	7	0.3	0.3	0.1	0.1	0.2	0.1	0.3	0.2
2013	8	8	0.3	0.3	0.2	0.1	0.3	0.2	0.3	0.2
2014	7	8	0.3	0.3	0.2	0.1	0.2	0.2	0.3	0.2
2015	6	6	0.3	0.2	0.1	0.1	0.2	0.1	0.2	0.2
2016	4	5	0.2	0.2	0.1	0.1	0.1	0.1	0.1	0.1
2017	6	4	0.2	0.2	0.1	0.1	0.2	0.1	0.2	0.1
2018	4	7	0.2	0.3	0.1	0.1	0.1	0.2	0.1	0.2
2019	5	7	0.2	0.3	0.1	0.1	0.2	0.1	0.2	0.2
2020	1	1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
1998-2020	114	164	0.2	0.3	0.1	0.1	0.2	0.2	0.2	0.3

The computation of the incidence measures includes all cancers, irrespective of first or subsequent malignancy.

Table 3 $\label{eq:Age_age} \mbox{Age distribution parameters by year of diagnosis (ALL PATIENTS) } \mbox{(incl. DCO)}$

Year of	Cases		Std.					Median		
diagnosis	n	Mean	dev.	Min.	Max.	10%	25%	50%	75%	90%
1998	5	70.5	8.4	61.6	84.4	61.6	68.4	69.0	69.4	84.4
1999	11	70.1	10.2	59.2	86.8	60.0	60.1	70.5	78.1	83.0
2000	6	67.3	8.3	57.7	78.5	57.7	58.9	66.9	74.6	78.5
2001	7	68.7	9.3	59.8	87.1	59.8	61.9	67.9	72.8	87.1
2002	14	67.4	16.3	39.5	88.6	39.5	53.2	72.3	79.7	84.6
2003	11	76.1	8.7	55.9	87.5	69.1	72.8	77.0	82.1	86.5
2004	11	73.9	10.1	58.2	91.0	59.7	61.9	77.6	79.3	81.3
2005	14	77.8	9.2	57.9	91.1	64.9	73.4	77.8	83.8	88.2
2006	13	69.3	7.5	59.1	80.9	59.4	61.3	70.8	74.9	79.9
2007	22	71.9	11.7	50.7	87.0	54.3	59.7	74.0	81.3	85.3
2008	12	76.1	5.7	65.3	86.5	71.8	72.9	74.7	80.7	82.2
2009	19	71.7	12.3	47.8	90.8	52.0	63.0	72.0	79.0	90.0
2010	10	76.6	7.1	65.8	88.5	68.0	71.7	75.4	80.8	87.4
2011	22	74.4	10.2	50.3	91.5	62.0	67.2	74.8	82.2	85.5
2012	14	78.8	9.1	61.2	91.7	64.2	73.9	80.2	86.6	90.3
2013	16	74.2	10.5	58.1	93.9	61.9	65.1	74.4	83.0	86.6
2014	15	72.3	9.7	56.7	92.3	59.5	66.2	70.1	80.0	86.2
2015	12	78.9	11.4	54.9	97.7	63.4	75.0	80.4	84.2	90.8
2016	9	75.3	5.7	67.5	86.0	67.5	69.5	76.4	77.3	86.0
2017	10	70.7	13.9	47.7	91.2	52.3	59.7	71.5	81.5	89.1
2018	11	74.9	9.8	60.1	97.4	65.7	67.6	72.9	80.3	81.1
2019	12	75.9	10.9	58.0	93.7	59.6	66.7	81.7	82.2	83.4
2020	2	70.4	22.0	54.8	86.0	54.8	54.8	70.4	86.0	86.0
1998-2020	278	73.5	10.6	39.5	97.7	59.4	67.0	74.6	81.5	86.6

Table 3a

Age distribution parameters by year of diagnosis (MALES) (incl. DCO)

Year of	Cases		Std.					Median		
diagnosis	n	Mean	dev.	Min.	Max.	10%	25%	50%	75%	90%
1998	1	69.0		69.0	69.0	69.0	69.0	69.0	69.0	69.0
1999	5	69.2	9.9	59.2	83.0	59.2	60.1	70.5	73.4	83.0
2000	3	70.3	11.1	57.7	78.5	57.7	57.7	74.6	78.5	78.5
2001	4	68.1	4.0	63.1	72.8	63.1	65.5	68.2	70.7	72.8
2002	4	57.0	23.3	39.5	88.6	39.5	39.5	50.0	74.6	88.6
2003	6	72.0	9.0	55.9	82.1	55.9	69.1	74.0	77.0	82.1
2004	5	68.6	9.0	58.2	77.6	58.2	59.7	72.2	75.2	77.6
2005	5	80.7	3.2	76.4	83.8	76.4	78.2	82.4	82.9	83.8
2006	5	70.6	7.4	59.1	79.9	59.1	70.8	71.0	72.1	79.9
2007	7	70.6	13.1	50.7	84.6	50.7	53.7	74.7	79.1	84.6
2008	4	73.9	2.7	71.8	77.8	71.8	72.2	72.9	75.5	77.8
2009	6	70.2	4.9	63.0	76.2	63.0	67.9	69.3	75.5	76.2
2010	3	78.8	8.6	71.7	88.5	71.7	71.7	76.4	88.5	88.5
2011	8	71.0	11.5	50.3	85.5	50.3	64.6	70.6	80.7	85.5
2012	7 /	77.4	8.4	64.2	91.7	64.2	73.9	76.9	82.4	91.7
2013	8	68.3	8.2	58.1	83.6	58.1	63.2	66.3	72.9	83.6
2014	7	68.3	6.3	59.5	77.6	59.5	65.7	66.3	75.8	77.6
2015	6	79.0	9.8	63.4	90.8	63.4	73.6	79.7	86.9	90.8
2016	4	74.7	5.0	67.5	78.9	67.5	71.7	76.3	77.8	78.9
2017	6 \	69.6	15.0	47.7	86.9	47.7	57.0	72.4	81.5	86.9
2018	4	71.0	9.7	60.1	80.3	60.1	62.9	71.8	79.1	80.3
2019	5	66.7	9.7	58.0	82.4	58.0	59.6	66.2	67.3	82.4
2020	1	86.0		86.0	86.0	86.0	86.0	86.0	86.0	86.0
1998-2020	114	71.3	10.2	39.5	91.7	58.2	65.7	72.7	78.2	83.0

Table 3b

Age distribution parameters by year of diagnosis (FEMALES) (incl. DCO)

Year of	Cases		Std.					Median		
diagnosis	n	Mean	dev.	Min.	Max.	10%	25%	50%	75%	90%
1998	4	70.9	9.6	61.6	84.4	61.6	65.0	68.9	76.9	84.4
1999	6	70.8	11.4	60.0	86.8	60.0	61.3	69.3	78.1	86.8
2000	3	64.2	4.6	58.9	67.2	58.9	58.9	66.6	67.2	67.2
2001	3	69.6	15.2	59.8	87.1	59.8	59.8	61.9	87.1	87.1
2002	10	71.5	11.6	50.5	84.6	51.9	67.3	75.3	79.7	83.3
2003	5	80.9	6.0	73.4	87.5	73,4	77.9	79.3	86.5	87.5
2004	6	78.4	9.4	61.9	91.0	61.9	78.3	78.9	81.3	91.0
2005	9	76.2	11.2	57.9	91.1	57.9	70.3	75.2	87.7	91.1
2006	8	68.6	7.9	59.4	80.9	59.4	61.0	67.8	75.2	80.9
2007	15	72.5	11.5	54.3	87.0	55.6	59.7	72.1	81.5	86.6
2008	8	77.3	6.6	65.3	86.5	65.3	73.5	77.8	81.9	86.5
2009	13	72.3	14.7	47.8	90.8	52.0	60.8	73.9	85.5	90.0
2010	7	75.6	6.8	65.8	86.3	65.8	70.1	74.4	80.8	86.3
2011	14	76.4	9.2	62.0	91.5	64.0	68.3	77.2	83.0	89.7
2012	7 /	80.1	10.3	61.2	90.3	61.2	71.4	82.8	86.8	90.3
2013	8	80.1	9.5	63.6	93.9	63.6	74.9	80.1	86.5	93.9
2014	8	75.7	11.3	56.7	92.3	56.7	69.5	75.6	83.4	92.3
2015	6	78.7	13.8	54.9	97.7	54.9	76.4	80.9	81.5	97.7
2016	5	75.8	6.8	69.5	86.0	69.5	69.5	76.4	77.3	86.0
2017	4	72.2	14.2	59.7	91.2	59.7	61.5	69.0	82.9	91.2
2018	7	77.1	9.9	67.6	97.4	67.6	71.8	72.9	81.1	97.4
2019	7	82.6	5.9	73.3	93.7	73.3	81.5	82.0	83.4	93.7
2020	1	54.8		54.8	54.8	54.8	54.8	54.8	54.8	54.8
1998-2020	164	75.0	10.6	47.8	97.7	59.8	68.0	76.4	82.0	87.4

Age at diagnosis Years	Cases n	% Cum.%	Males n	000	Cum.%	Females	90	Cum.%
0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44								
45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+	32 34 30	1.1 1.1 4.3 5.4 5.4 10.8 7.0 17.7 14.0 31.7 17.2 48.9 18.3 67.2 16.1 83.3 16.7 100.0	1 3 5 7 17 10 18 8 7	1.3 3.9 6.6 9.2 22.4 13.2 23.7 10.5 9.2	1.3 5.3 11.8 21.1 43.4 56.6 80.3 90.8 100.0	1 5 5 6 9 22 16 22 24	0.9 4.5 4.5 5.5 8.2 20.0 14.5 20.0 21.8	0.9 5.5 10.0 15.5 23.6 43.6 58.2 78.2
All ages	186 10	00.0	76	100.0		110	100.0	

 $$\operatorname{\textsc{Table}}$5$$ Age-specific incidence, DCO rate and proportion of all cancers for period 2007-2020

							Males	Females
			Males	Females	Males	Females		Prop.all
Age at			Age-			DCO rate	_	_
diagnosis	Males	Females	/-	spec.	n=0	n=0		n=155051
Years	n	n	7	incid.	%	%	엉	%
0-4								
5- 9								
10-14								
15-19								
20-24								
25-29								
30-34								
35-39								
40 - 44								
45-49	1	1	0.0	0.0			0.0	0.0
50-54	3	5	0.1	0.2			0.0	0.0
55-59	5	5	0.2	0.2			0.0	0.0
60-64	7	6	0.4	0.3			0.0	0.0
65-69	17	9	1.0	0.5			0.1	0.0
70-74	10	22	0.7	1.3			0.0	0.1
75-79	18	16	1.5	1.1			0.1	0.1
80-84	8	22	1.1	2.1			0.1	0.1
85+	7	24	1.5	2.3			0.1	0.1
All ages	76	110			0.0	0.0	0.0	0.1
Incidence								
Raw			0.2	0.3				
WS			0.1	0.1				
ES			0.2	0.2				
BRD-S			0.2	0.2				

The age-specific incidence characterizes the disease risk in a particular age group. The age distribution depends on the patient population frequency in each age group and reflects the tangible clinical picture of everyday patients care (see following chart).

ICD-10 C73: Anaplastic thyroid carcinoma (ATC)

Age distribution and age-specific incidence 2007 - 2020 (Males: 76, Females: 110)





Figure 6. Age distribution (males: mean=72.1 yrs, median=73.2 yrs; females: mean=76.0 yrs, median=77.3 yrs) and age-specific incidence.





55-59

FEMALES

75-79

Age at diagnosis (years)

85+

Figure 6a. Age-specific incidence in MCR registry areas compared to SEER (Surveillance, Epidemiology, and End Results, USA).

MALES



Reference:

Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence - SEER 21 Regs Research Data, released April 2021, based on the November 2020 submission. http://www.seer.cancer.gov.

Table 7a

Standardized incidence ratio (SIR, with 95% confidence limits), excess absolute risk (EAR) and DCO rate of further malignancies for period 1998-2020

MALES

erved Ex	pected		CI	CI		DC
n	n	SIR	95%	95%	EAR	
1 /	0.0	21.5	0.5	119.8	61.0	
1 /	0.0	68.6	1.7	382.4	# 63.0	
1/	0.7	1.5	0.0	8.2	20.5	
1	0.1	11.6	0.3	64.7	58.5	
1	0.0	31.7	0.8	176.6	62.0	
2	0.0	127.3	15.4	459.9	# 126.9	
1	0.0	25.0	0.6	139.2	61.4	
0	1.6	0.0	0.0	2.4	-99.4	
8	2.5	3.2	1.4	6.4	# 353.8	
	113	3				
(years)	60.6	5				
	156	5				
	1.4	1				
)	0.3	3				
	n 1 1 1 1 1 2 1 0 8 (years)	1 0.0 1 0.0 1 0.7 1 0.1 1 0.0 2 0.0 1 0.0 0 1.6 8 2.5 (years) 60.6 156	n n SIR 1 0.0 21.5 1 0.0 68.6 1 0.7 1.5 1 0.1 11.6 1 0.0 31.7 2 0.0 127.3 1 0.0 25.0 0 1.6 0.0 8 2.5 3.2 (years) 60.6 156 1.4	n n SIR 95% 1 0.0 21.5 0.5 1 0.0 68.6 1.7 1 0.7 1.5 0.0 1 0.1 11.6 0.3 1 0.0 31.7 0.8 2 0.0 127.3 15.4 1 0.0 25.0 0.6 0 1.6 0.0 0.0 8 2.5 3.2 1.4 (years) 60.6 156 1.4	n n SIR 95% 95% 1 0.0 21.5 0.5 119.8 1 0.0 68.6 1.7 382.4 1 0.7 1.5 0.0 8.2 1 0.1 11.6 0.3 64.7 1 0.0 31.7 0.8 176.6 2 0.0 127.3 15.4 459.9 1 0.0 25.0 0.6 139.2 0 1.6 0.0 0.0 2.4 8 2.5 3.2 1.4 6.4 (years) 60.6 156 1.4	n n SIR 95% 95% EAR 1 0.0 21.5 0.5 119.8 61.0 1 0.0 68.6 1.7 382.4 # 63.0 1 0.7 1.5 0.0 8.2 20.5 1 0.1 11.6 0.3 64.7 58.5 1 0.0 31.7 0.8 176.6 62.0 2 0.0 127.3 15.4 459.9 # 126.9 1 0.0 25.0 0.6 139.2 61.4 0 1.6 0.0 0.0 2.4 -99.4 8 2.5 3.2 1.4 6.4 # 353.8 (years) 60.6 156 1.4

The occurrence of further specified malignancy is statistically significant.

Table 7b


Standardized incidence ratio (SIR, with 95% confidence limits), excess absolute risk (EAR) and DCO rate of further malignancies for period 1998-2020

FEMALES

	Observed Ex	pected		CI	CI		DCO
Diagnosis	/ n /	n	SIR	95%	95%	EAR	용
C15 Oesophagus	/ 1 /	0.0	75.4	1.9	420.0	# 63.8	
C19-C20 Rectum	/ 1/	0.1	13.0	0.3	72.4	59.7	
C33-C34 Lung	1/	0.1	6.7	0.2	37.2	55.0	
C64 Kidney	1	0.0	22.4	0.6	124.7	61.8	100.0
C70-C72 CNS cancer	1	0.0	39.7	/1.0	221.0	# 63.1	
Not observed	0	1.6	0.0	0.0	2.3	-103	
All further malignancies	5	1.9	2.6	0.9	6.1	200.1	20.0
-							
Patients		163					
Median age at next malignan	cy (years)	75.1					
Person-years		155					
Mean observation time (year	s)	0.9					
Median observation time (ye	•	0.3					
(2)	•						

The occurrence of further specified malignancy is statistically significant.

Average incidence (Germany 1987 standard population) 2007 - 2020: Males



werage incidence (Germany 1987 standard population) 2007 - 2020: Females





Figure 8a. Map of cancer incidence (german standard population, incl. DCO cases) by county averaged for period 2007 to 2020. According to their individual incidence rates, the counties are displayed in different red and blue hues, being the fine white color attributed to the population mean (males 0.2/100,000 WS N=76, females 0.2/100,000 WS N=110).

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 67,727 female residents (averaged) in the period from 2007 to 2020 a total of 2 women were identified with newly diagnosed anaplastic thyroid ca.. Therefore, the mean incidence rate for this cancer type in this area can be calculated at 0.1/100,000 (german standard population). Though, the value of this parameter may vary with an underlying probability of 99% between 0.0 and 0.8/100,000.

Standardized incidence ratio (SIR) 2007 - 2020: Males



Standardized incidence ratio (SIR) 2007 - 2020: Females




Figure 8b. Map of standardized incidence ratio (SIR, incl. DCO cases) by county averaged for period 2007 to 2020. According to their individual SIR values, the counties are displayed in different red and blue hues, being the fine white color attributed to the population overall of 1.0 (males N=76, females N=110).

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 67,153 female residents (averaged) in the period from 2007 to 2020 a total of 2 women were identified with newly diagnosed anaplastic thyroid ca.. Therefore, the mean standardized incidence ratio (SIR) for this cancer type in this area can be calculated at 0.68. Though, the value of this parameter may vary with an underlying probability of 99% between 0.04 and 3.15, and is therefore not statistically striking.

MORTALITY

Table 9a

Annual cohorts: Incident cancers, follow-up status, proportion of DCO, deaths among the annual cohorts and proportion of available death certificates (with respect to registry area expansion from 2.65 to 4.10 m as of 2002, and from 4.10 to 4.94 m as of 2007, respectively)

						D
		Dwan				Prop. deaths
	Incident	Prop.	Dwan		Danas	with death
V		actively	Prop.	DW-	Prop.	
Year of	cases	followed	DCO	Deaths	deaths	certific.
diagnosis	n	90	90	n	%	6
1998	5	100.0		5	100.0	80.0
1999	11	100.0		9	81.8	88.9
2000	6	100.0		5	83.3	100.0
2001	7/	100.0		7	100.0	100.0
2002	1/4	100.0		13	92.9	92.3
2003	11 /	100.0		10	90.9	100.0
2004	11	100.0		11	100.0	100.0
2005	14	100.0		13	92.9	100.0
2006	13	92.3		12	92.3	100.0
2007	22	95.5		19	86.4	100.0
2008	12	100.0		10	83.3	90.0
2009	19	100.0		18	94.7	100.0
2010	10	100.0		10	100.0	100.0
2011	22	100.0		20	90.9	95.0
2012	14	100.0		14	100.0	100.0
2013	16	100.0		15	93.8	100.0
2014	15	93.3		14	93.3	100.0
2015	12	100.0		10	83.3	100.0
2016	9	100.0		9	100.0	88.9
2017	10	90.0		9	90.0	88.9
2018	11	100.0		8	72.7	62.5
2019	12	100.0		9	75.0	66.7
2020	2	100.0		1	50.0	100.0
1998-2020	278	98.6		251	90.3	94.8

Table 9b

Annual cohorts of incident cancers and deaths, proportion of death certificates and cases deceased within the same year of being diagnosed with cancer (incl. DCO)

(with respect to registry area expansion from 2.65 to 4.10 m as of 2002, and from 4.10 to 4.94 m as of 2007, respectively)

		Prop.		Duran
Ingidont			Dooths in	Prop. deaths in
	Doaths			same year
	7 - 7	/	4	%
11		6	11	6
5	5	80.0	/ 1	20.0
11	8	87.5	5	45.5
6	6	83.3	2	33.3
7	8	100.0	5	71.4
14	13	92.3	8	57.1
11	10	100.0	7	63.6
1,1	14	100.0	7	63.6
14	12	100.0	10	71.4
13	12	100.0	_ 8	61.5
22	15	100.0	10	45.5
12	14	100.0	5	41.7
19	14	100.0	9	47.4
10	14	100.0	7	70.0
22	18	100.0	14	63.6
14	14	100.0	9	64.3
16	15	100.0	10	62.5
15	20	100.0	12	80.0
12	12	100.0	/6	50.0
9	14	92.9	8	88.9
10	7	100.0	6	60.0
11	8	62.5	4	36.4
12	11	45.5	6	50.0
2	6	83.3	1	50.0
278	270	94.4	160	57.6
	11 6 7 14 11 11 14 13 22 12 19 10 22 14 16 15 12 9 10 11 12 2	cases Deaths n n 5 5 11 8 6 6 7 8 14 13 11 14 14 12 13 12 22 15 12 14 19 14 10 14 22 18 14 14 16 15 15 20 12 12 9 14 10 7 11 8 12 11 2 6	Cases Deaths Certific.	Incident cases Deaths with death certific. same year n n n % n n n n n n n n n n n n n n n

Table 9c

Annual cohorts of deaths, proportion of cancer-related and non-cancer-related deaths, and cancer recorded on death certificates (incl. DCO)

(with respect to registry area expansion from 2.65 to 4.10 m as of 2002, and from 4.10 to $4.94~\mathrm{m}$ as of 2007, respectively)

				Prop.
				cancer
		Prop.	Prop.	recorded
		cancer-	non-cancer-	on death
Year of	Deaths	related	related	certificate
death	n	્રે	િ	ଚ
1998	5	80.0	20.0	100.0
1999	8	87.5	12.5	100.0
2000	6	83.3	16.7	100.0
2001	8	100.0		100.0
2002	13	92.3	7.7	100.0
2003	10	90.0	10.0	100.0
2004	14	92.9	7.1	92.9
2005	12	100.0		100.0
2006	12	100.0		100.0
2007	15	100.0		100.0
2008	14	100.0		100.0
2009	14	85.7	14.3	100.0
2010	\ 14	92.9	7.1	92.9
2011	18	100.0		100.0
2012	14	92.9	7.1	100.0
2013	15	100.0		100.0
2014	20	85.0	15.0	90.0
2015	12	91.7	8.3	100.0
2016	14	85.7	14.3	100.0
2017	7	85.7	14.3	85.7
2018	8	75.0	25.0	80.0
2019	11	81.8	18.2	80.0
2020	6	66.7	33.3	100.0
1998-2020	270	91.5	8.5	97.3

Year of death	Deaths n	Age at death (all causes) Years	Age at death (cancer-related) Years	Age at death (non-cancer-related) Years	Age at death (according to death certificate)
1998					
1999	3	70.5	70.5		76.8
2000	3	74.0	69.3	74.0	69.3
2001	4	70.5	70.5	/ / /	70.5
2002	2	75.8	75.8		75.8
2003	3	77.4	77.4		77.4
2004	9	70.7	71.5	50.0	71.5
2005	4	82.7	82.7		82.7
2006	4	71.1	71.1		71.1
2007	4	74.2	74.2		74.2
2008	3	78.3	78.3		78.3
2009	/3	76.4	74.5	76.4	76.4
2010	6	71.0	69.7	76.0	69.7
2011	5	82.3	82.3		82.3
2012	8	76.1	76.1		76.1
2013	6	68.3	68.3		68.3
2014	10	66.9	66.6	86.5	66.9
2015	7	73.9	70.4	88.5	73.9
2016	7	76.7	76.7		76.7
2017	6	79.4	76.7	84.2	76.7
2018	3	78.3	66.0	79.4	66.0
2019	5	63.6	63.6		72.2
2020	3	86.2	73.2	89.2	73.2
1998-2020	108	74.2	73.4	79.4	74.7

Deaths of patients are considered to be cancer-related, in case that fact was recorded on the death certificate, or patients had suffered from metastasis or recurrence.

 $\begin{tabular}{ll} Table 10b \\ \hline \begin{tabular}{ll} Medians of age at death according to the grouping in Table 9 \\ \hline \begin{tabular}{ll} FEMALES \end{tabular}$

					Age at
		Age at	Age at	Age at	death
		death	death	death	(according
		(all	(cancer-	(non-cancer-	to death
Year of	Deaths	causes)	related)	related)	certificate)
death	n	Years	Years	Years	Years
1998	5	75.5	79.3	63.5	79.3
1999	5	68.9	73.5	60.5	68.9
2000	3	71.7	71.7		71.7
2001	4	67.3	67.3		67.3
2002	11	76.5	76.6	74.9	76.6
2003	7	78.5	80.5	53.2	78.5
2004	5	79.4	79.4		79.4
2005	8	79.4	79.4		79.4
2006	8	75.3	75.3		75.3
2007	11/	81.7	81.7		81.7
2008	1,1	73.2	73.2		73.2
2009	11	74.6	74.6	83.8	74.6
2010	8	76.1	76.1		76.1
2011	13	78.1	78.1		78.1
2012	6	80.6	81.8	74.7	80.6
2013	\9	82.6	82.6		82.6
2014	10	79.6	78.9	83.5	78.9
2015	5	80.5	80.5		80.5
2016	7	76.4	76.4	76.4	76.4
2017	1	63.5	63.5		63.5
2018	5	71.6	71.6		72.3
2019	6	81.9	81.9	81.0	75.8
2020	3	82.3	78.5	82.4	82.3
1998-2020	162	78.0	78.1	77.5	78.0

By 2018, Bavarians' life expectancy at birth is estimated at 79.3 years for boys and 83.8 years for girls.

Deaths of patients are considered to be cancer-related, in case that fact was recorded on the death certificate, or patients had suffered from metastasis or recurrence.

Table 11a $\begin{tabular}{ll} Mortality measures (cancer-related death) and mortality-incidence-index \\ by year of death \\ MALES \end{tabular}$

Year of	Deaths	Mort.	MI-Index	Mort. N	MI-Index	Mort. M	I-Index	Mort.	MI-Index
death	n	raw	raw	WS	WS	ES	ES	BRD-S	BRD-S
1998									
1999	3	0.3	0.60	0.2	0.64	0.3	0.66	0.4	0.72
2000	2	0.2	0,67	0.1	0.64	0.1	0.61	0.2	0.67
2001	4	0.3	1.00	0.2	0.92	0.3	1.01	0.4	1.19
2002	2	0.1	0.50	0.1	0.47	0.1	0.55	0.1	0.60
2003	3	0.2	0.50	0.1	0.44	0.1	0.45	0.2	0.51
2004	8	0.4	1.60	0.2	1.58	0.4	1.54	0.5	1.56
2005	4	0.2	0.80	0.1	0.78	0/. 1	0.78	0.3	0.81
2006	4	0.2	0.80	0.1	0.82	0.2	0.78	0.2	0.81
2007	4	0.2	0.57	0.1	0.52	0.1	0.54	0.2	0.58
2008	3	0.1	0.75	0.1	0.69	0.1	0.77	0.2	0.90
2009	2	0.1	0.33	0.0	0.25	0.1	0.30	0.1	0.35
2010	5	0.2	1.67	0.1	2.40	0.2	1.78	0.2	1.41
2011	5	0.2	0.63	0.1	0.50	0.2	0.60	0.2	0.68
2012	8	0.4	1.14	0.1	1.10	0.2	1.08	0.3	1.12
2013	6	0.3	0.75	0.1	0.72	0.2	0.75	0.3	0.74
2014	9	0.4	1.29	0.2	1.27	0.3	1.27	0.4	1.28
2015	6	0.3	1.00	0.1	1.45	0.2	1.23	0.2	1.02
2016	7	0.3	1.75	0.1	1.82	0.2	1.78	0.3	1.79
2017	5	0.2	0.83	0.1	0.79	0.1	0.79	0.2	0.84
2018	1	0.0	0.25	0.0	0.37	0.0	0.34	0.0	0.26
2019	5	0.2	1.00	0.1	1.08	0.2	1.02	0.2	1.04
2020	2	0.1	2.00	0.0	3.37	0.1	2.48	0.1	2.27
1998-2020	98	0.2	0.86	0.1	0.85	0.2	0.85	0.2	0.87

Table 11b $\label{lem:mortality} \mbox{Mortality measures (cancer-related death) and mortality-incidence-index } \mbox{by year of death} \mbox{FEMALES}$

			/						
Year of			MI-Index				MI-Index		MI-Index
death	n	raw	raw	WS	WS	ES	ES	BRD-S	BRD-S
1998	4	0.3	1.00	0.1	0.51	0.2	0.67	0.3	0.97
1999	4	0.3	0.67	0.1	0.73	0.2	0.72	0.3	0.76
2000	3	0.2	1.00	0.1	0.66	0.2	0.75	0.2	0.82
2001	4	0.3	1.33	0.2	1.45	0.2	1.36	0.3	1.40
2002	10	0.5	1.00	0.2	0.81	0.3/	0.88	0.5	1.01
2003	6	0.3	1.20	0.1	1.34	0.2	1.20	0.2	1.14
2004	5	0.3	0.83	0.1	1.13	0.2	0.99	0.2	0.86
2005	8	0.4	0.89	0.1	0.71	0.2	0.77	0.3	0.84
2006	8	0.4	1.00	0.1	0.72	0.2	0.81	0.3	0.91
2007	11	0.5	0.73	0.1	0.52	0.2	0.56	0.3	0.66
2008	11	0.5	1.38	0.2	1.62	0.3	1.55	0.4	1.45
2009	10	0.4	0.77	0.2	0.75	0.2	0.73	0.3	0.69
2010	8	0.3	1.14	0.1	1.29	0.2	1.29	0.3	1.26
2011	13	0.6	0.93	0.2	0.77	0.3	0.82	0.4	0.87
2012	5	0.2	0.71	0.1	0.70	0.1	0.74	0.1	0.76
2013	9	0.4	1.13	0.1	1.31	0.2	1.22	0.3	1.18
2014	8	0.3	1.00	0.1	0.93	0.2	0.95	0.2	1.01
2015	5	0.2	0.83	0.0	0.60	0.1	0.69	0.1	0.80
2016	5	0.2	1.00	0.1	0.99	0.1	1.02	0.1	1.02
2017	1	0.0	0.25	0.0	0.38	0.0	0.33	0.0	0.32
2018	5	0.2	0.71	0.1	0.91	0.1	0.85	0.2	0.76
2019	4	0.2	0.57	0.0	0.66	0.1	0.63	0.1	0.62
2020	2	0.1	2.00	0.0	0.93	0.0	1.07	0.1	1.75
2020	4	0.1	2.00	3.0	0.33	0.0	1,0,	/ 5.1	1.70
1998-2020	149	0.3	0.91	0.1	0.83	0.2	0.85	0.2	0.89

Table 12

Age distribution of age at death (cancer-related) for period 2007-2020 (incl. multiple malignancies)

Age at death Years	Cases n	% Cu	Males n	્	Cum.%	Females n	90	Cum.%
0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39								
40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+	2 3 8 16 20 28 30 30 28	1.8 4.8 9.7 1 12.1 2 17.0 4 18.2 6 18.2 8	1.2 1 3.0 1 7.9 4 7.6 9 9.7 14 6.7 10 4.8 16 3.0 7 0.0 6	1.5 1.5 5.9 13.2 20.6 14.7 23.5 10.3 8.8	1.5 2.9 8.8 22.1 42.6 57.4 80.9 91.2 100.0	1 2 4 7 6 18 14 23 22	1.0 2.1 4.1 7.2 6.2 18.6 14.4 23.7 22.7	1.0 3.1 7.2 14.4 20.6 39.2 53.6 77.3 100.0
All ages	165	100.0	68	100.0		97	100.0	

Table 13

Age-specific mortality (cancer-related) and proportion of all cancers for period 2007-2020

(incl. multiple malignancies)

		Males		Females		Males	Females
Age at		Age-		Age-			Prop.all
death	Males Fema	/= /		spec.		cancers	cancers
Years	n n	/ - /	MI-index		MT-index		%
Icaro		morear.	111 1114011	morcar.	III IIIdeii	Ŭ	,
0- 4							
5- 9							
10-14							
15-19							
20-24							
25-29							
30-34							
35-39							
40-44							
45-49	1	1 0.0	1.00	0 0	1.00	0.1	0.1
				0.0			
50-54		2 0.0	0.33	0.1	0.40	0.0	0.1
55-59		0.2	0.80	0.2	0.80	0.1	0.1
60-64		7 0.5	1.29	0.4	1.17	0.1	0.1
65-69		6 0.9	0.82	0.3	0.67	0.2	0.1
70-74	10 13		1.00	1.0	0.82	0.1	0.2
75-79	16 1		0.89	0.9	0.88	0.1	0.1
80-84	7 2		0.88	2.2	1.05	0.1	0.2
85+	6 2	2 1.3	0.86	2.1	0.92	0.1	0.2
All ages	68 9	7				0.1	0.2
Mortality							
Raw		0.2	0.89	0.3	0.88		
WS		0.1	0.90	0.1	0.84		
ES		0.1	0.90	0.1	0.85		
BRD-S		0.2	0.90	0.2	0.87		
PYLL-70							
per 100,000		0.7		0.6			
ES		0.6		0.5			
AYLL-70		6.6		8.8			

					Syn- chron	Syn- chron		
	Total	Total	Pre	Pre	±30d	±30d	Post	Post
Diagnosis	n	%↓	n	←%	n	~ %	n	←%
C15 Oesophagus	/ 1	3.6					1	100.0
C18 Colon	2	7.1	2	100.0				
C32 Larynx	/ 1 /	3.6	1	100.0				
C33-C34 Lung	/ 1 -	3.6	1	100.0				
C43 Malign. melanoma	3	10.7	3	100.0				
C44 Skin others	2	7.1	2	100.0				
C46,C49 Soft tissue	2	7.1	1	50.0	1	50.0		
C61 Prostate	9	32.1	9	100.0				
C64 Kidney	3	10.7	2	66.7			1	33.3
C69 Eye melanoma	1	3.6	1	100.0				
C70-C72 CNS cancer	2	7.1	1	50.0			1	50.0
C73 Thyroid	1_	3.6			1	100.0		
All further malignancies	28	100.0	23	82.1	2	7.1	3	10.7

ICD-10 C44 (Other malignant neoplasms of skin) is not systematically recorded by MCR and therefore not considered for evaluation as a particular primary but at least as a further malignancy.

Table 14b

Further malignancies in deaths in period 1998-2020

FEMALES

					Syn- chron	Syn- chron		
	Total	Total	Pre	Pre	±30d	±30d	Post	Post
Diagnosis	n	%↓	n	← %	n	← %	n	← %
C18 Colon	7	20.6	7	100.0				
C19-C20 Rectum	2	5.9	_ 1	50.0			1	50.0
C33-C34 Lung	4	11.8	3	75.0			1	25.0
C46,C49 Soft tissue	1	2.9	1	100.0				
C50 Breast	10	29.4	10	100.0				
C53 Cervix uteri	1	2.9	1	100.0				
C54 Corpus uteri	1	2.9	1	100.0				
C64 Kidney	5	14.7	4	80.0			1	20.0
C73 Thyroid	1	2.9			1	100.0		
C82-C85 NHL	2	5.9	2	100.0				
All further malignancies	34	100.0	30	88.2	1	2.9	3	8.8

ICD-10 C44 (Other malignant neoplasms of skin) is not systematically recorded by MCR and therefore not considered for evaluation as a particular primary but at least as a further malignancy.

Table 15

Age-specific mortality (cancer-related) and proportion of all cancers for period 2007-2020 (First primaries only *)

		Males		Females		Males	Females
Age at		Age-		Age-			Prop.all
death	Males Femal			spec.		cancers	cancers
Years	n n	/ - /	MT-index	- \	MI-index		%
10010						Ů	/
0- 4							
5- 9							
10-14							
15-19							
20-24							
25-29							
30-34							
35-39							
40-44							
45-49	1 1	0.0	1.00	0.0	1.00	0.1	0.1
50-54	1 2		0.33	0.1	0.50	0.0	0.1
55-59	4 3		0.80	0.1	0.75	0.1	0.1
60-64	6 6		1.50	0.3	1.20	0.1	0.1
65-69	9 5	0.6	0.82	0.3	0.71	0.1	0.1
70-74	8 14	0.5	1.14	0.8	0.88	0.1	0.2
75-79	13 8	1.1	0.87	0.5	0.73	0.1	0.1
80-84	3 18	0.4	0.75	1.7	1.13	0.0	0.2
85+	2 17	0.4	0.67	1.6	0.89	0.0	0.2
All ages	47 74					0.1	0.2
- 3							
Mortality							
Raw		0.1	0.89	0.2	0.89		
WS		0.1	0.91	0.1	0.86		
ES		0.1	0.89	0.1	0.86		
BRD-S		0.1	0.89	0.2	0.89		
DIAD 5		0.1	0.05	0.2	0.05		
PYLL-70							
per 100,000		0.5		0.5			
_				0.3			
ES		0.5					
AYLL-70		7.5		9.0			

^{*} See corresponding tables with multiple malignancies.

Table 16

Age-specific mortality (cancer-related) and proportion of all cancers for period 2007-2020

(Single primaries only *)

			Males		Females		Males	Females
Age at			Age-		Age-		Prop.all	Prop.all
death	Males	Females	spec.		spec.		cancers	cancers
Years	n	n		MI-index	mortal.	MI-index	%	%
0- 4								
5- 9								
10-14								
15-19								
20-24								
25-29								
30-34								
35-39								
40-44								
45-49	1	1	0.0	1.00	0.0	1.00	0.1	0.1
50-54	1	2	0.0	0.50	0.1	0.50	0.0	0.1
55-59	3 /	3	0.1	0.60	0.1	0.75	0.1	0.1
60-64	5	6	0.1	1.25	0.3	1.20	0.1	0.2
65-69	9	5	0.6	0.82	0.3	0.71	0.1	0.1
70-74	8	14	0.5	1.14	0.8	0.71	0.1	0.1
75-79	13	7	1.1	0.87	0.5	0.70	0.1	0.2
80-84	3	18	0.4	0.87	1.7	1.13	0.0	0.1
	2							
85+	2	16	0.4	0.67	1.5	0.89	0.0	0.2
711	4 5	72					0 1	0 0
All ages	45	12					0.1	0.2
7.								
Mortality				0.00				
Raw			0.1	0.87	0.2	0.90		
WS			0.1	0.87	0.1	0.87		
ES			0.1	0.86	0.1	0.87		
BRD-S			0.1	0.87	0.2	0.90		
PYLL-70								
			0.5		0.5			
per 100,000								
ES			0.4		0.4			
AYLL-70			7.2		9.0			

^{*} See corresponding tables with multiple malignancies.

ICD-10 C73: Anaplastic thyroid carcinoma (ATC) Age distribution and age-specific mortality 2007 - 2020 (Males: 68, Females: 97)

Figure 17. Distribution of age at death (bars; males: mean=71.3 yrs, median=72.0 yrs; females: mean=76.3 yrs, median=78.3 yrs) and age-specific mortality (all patients: solid line, patients with single primaries: dotted line). The age-specific incidence is additionally plotted for comparison (dashed line).


Age at death (years)

The difference between age at diagnosis (Table 3) and age at anaplastic thyroid ca.-related death (see Table 10) should be considered.



Age distribution (%)

werage mortality (Germany 1987 standard population) 2007 - 2020: Males



Average mortality (Germany 1987 standard population) 2007 - 2020: Females





Figure 18a. Map of cancer mortality (german standard population) by county averaged for period 2007 to 2020. According to their individual mortality rates, the counties are displayed in different red and blue hues, being the fine white color attributed to the population mean (males 0.2/100,000 WS N=68, females 0.2/100,000 WS N=97).

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 67,727 female residents (averaged) in the period from 2007 to 2020 a total of 2 women died from anaplastic thyroid ca.. Therefore, the mean mortality rate for this cancer type in this area can be calculated at 0.1/100,000 (german standard population). Though, the value of this parameter may vary with an underlying probability of 99% between 0.0 and 0.8/100,000.

Standardized mortality ratio (SMR) 2007 - 2020: Males



Standardized mortality ratio (SMR) 2007 - 2020: Females




Figure 18b. Map of standardized mortality ratio (SMR, incl. DCO cases) by county averaged for period 2007 to 2020. According to their individual SMR values, the counties are displayed in different red and blue hues, being the fine white color attributed to the population overall of 1.0 (males N=68, females N=97).

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 67,153 female residents (averaged) in the period from 2007 to 2020 a total of 2 women died from anaplastic thyroid ca.. Therefore, the mean standardized mortality ratio (SMR) for this cancer type in this area can be calculated at 0.77. Though, the value of this parameter may vary with an underlying probability of 99% between 0.04 and 3.59, and is therefore not statistically striking.

Statistical Notes

In all tables and figures the respective reference values should be carefully considered. The incidence rates include diagnoses (with multiple primary), and death certificate only (DCO) cases, where applicable. For mortality statistics patients, diagnoses and progressive course of disease are presented. In the calculations, all courses of disease are considered whereby progressions occurred and/or death certificate identified progressive cancers were ascertained. Additionally there are three groups of disease course to consider:

1. All multiple primaries included

The mortality statistic describes the tumor-specific death, independent of any malignancy. The patient perspective, induced secondary malignancies, and the problem of multiple malignancies from the same primary tumor all have reasons for their inclusion.

2. First singular primary (no information about other prior or synchronous malignancy)

The mortality statistic describes the cancer-related death for patients who have no therapeutic restrictions due to a previous or synchronous cancer. These statistics are comparable to studies that have exclusion criteria based on a second malignancy.

3. Single primary (no information about other prior, syn- or metachronous malignancy)

The mortality statistic describes the tumor-specific death that occurs without any impact through secondary primaries, earlier, synchronous, later or induced. Precisely the difference between disease group 1 and 2 highlight the magnitude of the problem of secondary malignancies.

For this reason differences appear concerning official mono-causal mortality statistics. To judge the maximum deviation, 2 further tables are presented. In the first table the distribution of secondary malignancies before, at or after the described cancer are shown, that could be an alternative cause of death. In the second table, the age-specific mortality rates for all courses of disease, without designation of secondary malignancies are shown.

A previously minimally acknowledged statistic is the **age at death**, which allows for a good assessment of the quality of classification of the apparent tumor-specific death. For assumed tumor-independent deaths, the age of death should be estimated from the age of diagnosis and the normal life expectancy, whereas tumor-dependent deaths can be estimated from the age of diagnosis plus the average tumor-specific life expectancy. The comparison of different tumors demonstrates this association, if the causes of cancer and the competing cause of death are independent of each other (e.g. breast and colon versus head&neck and lung).

The ratio of mortality and incidence (mortality-to-incidence ratio, **MIR**, **MI-Index**) is a statistical index that allows for the evaluation of the quality of data. For diseases with poor prognoses, comparable values are obtained from all age groups, because to a large extent, the numerator and denominator contain the same cases. For tumors with a good prognosis, increasing and decreasing incidence and age-specific differences in prognosis can more strongly alter the MIR. Additionally, attention should be paid to the confidence intervals where fewer cases are reported.

The complexity of problems identified here emphasizes the importance of relative survival data for the appropriate analysis of long term results.

As a measurement of the burden of disease, the number of potential life years loss due to premature deaths in a cohort can be calculated (**PYLL**, potential years of life lost, standardized per 100,000 persons or per European standard) as well as the average loss of life years per individual (**AYLL**, average years of life lost). Depending upon the analytic aim (health economy, prevention, health care research) different methods exist for the generation of these measurements. In the results presented here, the age for a premature death is considered to be before 70 years, according to the guidelines of the OECD and the WHO (as seen in the abbreviation PYLL-70 or AYLL-70).

Shortcuts

MCR Munich Cancer Registry (Tumorregister München)

GEKID Association of Population-based Cancer Registries in Germany

(Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V.)

SEER Surveillance, Epidemiology, and End Results (USA)

DCO Death certificate only

BRD-S German (FRG) standard population ES European standard population (old)

WS World standard population

SIR Standardized incidence ratio

CI Confidence interval EAR Excess absolute risk

= excess cancer cases (O - E) per 10,000 person-years

PYLL-70 Potential years of life lost prior to age 70 given a person dies before that age AYLL-70 Average years of life lost prior to age 70 given a person dies before that age

SMR Standardized mortality ratio

MI-index Ratio of mortality to incidence, MIR

FRG Federal Republic of Germany

Recommended Citation

Munich Cancer Registry. ICD-10 C73: Anaplastic thyroid ca. - Incidence and Mortality [Internet]. 2021 [updated 2021 Dec 21; cited 2022 Feb 1]. Available from: https://www.tumorregister-muenchen.de/en/facts/base/bC73A E-ICD-10-C73-Anaplastic-thyroid-ca.-incidence-and-mortality.pdf

Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.